Ensysce Biosciences Inc., a clinical-stage pharmaceutical company focused on developing innovative pain relief solutions, announced it has received a $5.3 million installment as part of a $15 million, three-year grant from the National Institute on Drug Abuse (NIDA). This funding will accelerate the development of PF614-MPAR, a next-generation opioid designed to reduce the risk of overdose while providing effective pain relief. This product has earned FDA Breakthrough Therapy designation, acknowledging its potential impact on pain management. The grant is solely awarded to Ensysce Biosciences, supporting the company's mission to deliver safer opioid alternatives and advance toward commercialization.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1035140) on June 04, 2025, and is solely responsible for the information contained therein.